Tumor mutational burden (TMB), defined as total somatic mutations per coding area of an exon, has also been associated with improved response to treatment with immune checkpoint inhibitors, including anti–PD-1 agents, that enhance antitumor T-cell activity8. Here, PDCD1 is linked to neoplasm.